Molecular diagnostic solutions provider Curetis has acquired real-time qPCR-based Gyronimo platform from Carpegen and Systec.
Under the deal, Curetis is purchasing all Gyronimo Platform assets, comprising of fully functional prototype systems.
It is also acquiring the whole intellectual property portfolio that includes several patent families pending and key patent granted in the US, Canada and China, as well as Europe.
The company will secure exclusive worldwide rights to the platform, including the right to sublicense, partner or sell it, with an exemption for Carpegen and Systec in dental testing, and environmental and food safety testing.
Curetis, which will acquire functional prototype instruments and cartridges, is planning to complete the IVD development and industrialization, and OEM manufacturing of systems and cartridge production.
Carpegen and Systec will receive one-time upfront payment of €5m, and is eligible for two discrete and one-time milestone payments of €2.5m upon platform and first cartridge CE marking and FDA clearance.
The companies will also secure a royalty-based earn-out of around €9m.
The acquisition enables Curetis to enhance the capabilities of Unyvero platform, helping to provide services ranging from rapid one hour testing for more than 10 diagnostic targets to multiplexed syndromic testing panels delivering results for around 100 diagnostic targets in 4 to 5 hours.
Incorporating Gyronimo into the Unyvero will enable Curetis to use the platform in applications such as infection control, viral testing and CNS infections, as well as applications for immunocompromised patients.
Curetis CEO Dr Oliver Schacht said: "We are truly excited about the transaction which offers us an excellent opportunity to accelerate the growth and development of our Unyvero Platform with complementary and greatly expanding characteristics.”